Skip to content

US · ALMS · BIOTECHNOLOGY

Alumis Inc. (ALMS) intrinsic value and stock valuation

$3.96as of 2026-11-21 · Mkt cap 3.35B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alumis Inc. DCF and intrinsic value

InvestorsCraft values ALMS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALMS’s statements →

Alumis Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 alumis.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$24.1M
20222025
Net income
-$-243.32M
20222025
Free cash flow
-$-370.18M
20222025
Total equity
$301.3M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$24.1M$0.00$0.00$0.00
Operating income-$-427.2M-$-300.75M-$-158.17M-$-113.85M
Net income-$-243.32M-$-294.23M-$-154.99M-$-111.93M
EPSd-$-286.16K-$-10.38M-$-2.99M-$-14.92M
Operating cash flow-$-369.52M-$-255.08M-$-129.97M-$-107.72M
Capital expenditure-$-650K-$-1.73M-$-4.5M-$-2.41M
Free cash flow-$-370.18M-$-256.81M-$-134.47M-$-110.13M
Total assets$411.9M$341M$89.6M$108.2M
Total debt$36.9M$30.7M$32.6M$1.78M
Net debt-$-52.76M-$-138.8M-$-13.42M-$-23.83M
Total equity$301.3M$260.1M-$-339.26M-$-195.24M
Cash and short-term investments$308.5M$288.3M$49M$92.9M
Income statement
2025202420232022
Revenue$24.1M$0.00$0.00$0.00
Cost of revenue$3.5M$3.15M$0.00$250K
Gross profit$20.6M-$-3.15M$0.00-$-250K
Research and development expenses$386M$265.6M$137.7M$101.1M
Selling, general and administrative expenses$91.9M$35.2M$20.5M$12.6M
Other expenses-$-30.1M-$-3.15M$0.00$0.00
Operating expenses$447.8M$297.6M$158.2M$113.6M
Cost and expenses$451.3M$300.8M$158.2M$113.9M
Interest income$14.2M$12M$3.37M$1.99M
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$3.5M$3.15M$1.28M$250K
Ebitda-$-248.39M-$-291.08M-$-153.71M-$-111.68M
Operating income-$-427.2M-$-300.75M-$-158.17M-$-113.85M
Total other income/expenses, net$175.3M$6.52M$3.18M$1.92M
Income before tax-$-251.89M-$-294.23M-$-154.99M-$-111.93M
Income tax expense-$-8.56M$0.00$0.00$0.00
Net income-$-243.32M-$-294.23M-$-154.99M-$-111.93M
Weighted average shares outstanding$850.3M$28.3M$51.8M$7.5M
Weighted average diluted shares outstanding$850.3M$28.3M$51.8M$7.5M
Balance sheet
2025202420232022
Cash and short-term investments$308.5M$288.3M$49M$92.9M
Net receivables$2.08M$1.81M$720K$500K
Inventory$0.00$0.00$0.00$0.00
Total current assets$318.2M$306.2M$53.4M$102.6M
Property, plant and equipment, net$35.2M$33.7M$35.2M$4.47M
Goodwill and intangible assets$51M$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$93.7M$34.8M$36.3M$5.61M
Total assets$411.9M$341M$89.6M$108.2M
Accounts payable$10.1M$9.62M$1.12M$1.72M
Short-term debt$4.67M$1.56M$1.72M$1.31M
Deferred revenue$1.46M$0.00$0.00$0.00
Total current liabilities$73.3M$50.9M$20.9M$13.4M
Long-term debt$32.2M$29.2M$30.9M$470K
Deferred revenue, non-current$2.61M$0.00$0.00$0.00
Total non-current liabilities$37.3M$30M$408M$290.1M
Capital lease obligations$32.2M$30.7M$32.6M$1.78M
Total liabilities$110.6M$80.9M$428.9M$303.4M
Common stock$10K$0.00$0.00$0.00
Retained earnings-$-901.88M-$-658.55M-$-364.32M-$-209.32M
Accumulated other comprehensive income (loss)$190K$40K$0.00-$-130K
Total equity$301.3M$260.1M-$-339.26M-$-195.24M
Total investments$218.8M$118.7M$2.96M$67.3M
Total debt$36.9M$30.7M$32.6M$1.78M
Net debt-$-52.76M-$-138.8M-$-13.42M-$-23.83M
Cash flow statement
2025202420232022
Net income-$-243.32M-$-294.23M-$-154.99M-$-111.93M
Depreciation and amortization$3.5M$3.15M$1.28M$250K
Stock-based compensation$43.5M$19.5M$8.62M$5.96M
Change in working capital$26.3M$14.8M$12.1M-$-1.92M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-6.04M$8.51M-$-640K$1.29M
Net cash provided by operating activities-$-369.52M-$-255.08M-$-129.97M-$-107.72M
Investments in property, plant and equipment-$-650K-$-1.73M-$-4.5M-$-2.41M
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities$287.9M-$-113.79M$60.5M-$-68.75M
Common stock issued$2.08M$193.3M$0.00$0.00
Common stock repurchased-$-20K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.07M$492.4M$89.7M$101.6M
Net change in cash-$-79.58M$123.5M$20.2M-$-74.85M
Cash at end of period$91.1M$170.6M$47.1M$27M
Operating cash flow-$-369.52M-$-255.08M-$-129.97M-$-107.72M
Capital expenditure-$-650K-$-1.73M-$-4.5M-$-2.41M
Free cash flow-$-370.18M-$-256.81M-$-134.47M-$-110.13M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alumis Inc.

        Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

        CEO
        Martin Babler
        Employees
        224
        Beta
        -0.71

        Explore

        Frequently asked questions

        What is the intrinsic value of Alumis Inc. (ALMS)?

        InvestorsCraft does not currently publish an intrinsic value for ALMS. How the IC value is calculated.

        Is ALMS undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALMS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.